{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:44:33Z","timestamp":1794998673847,"version":"4.9.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>\n                      To compare 6-month safety and efficacy outcomes of fractionated CO\n                      <jats:sub>2<\/jats:sub>\n                      laser (laser) with topical clobetasol propionate (steroid) for treatment of symptomatic vulvar lichen sclerosus.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      We conducted a single-center randomized controlled trial that compared fractionated CO\n                      <jats:sub>2<\/jats:sub>\n                      laser with steroid treatment for patients with biopsy-proven lichen sclerosus. Randomization was stratified by prior clobetasol propionate use. The primary outcome was mean change in Skindex-29 score at 6 months. A total sample size of 52 participants were recruited to detect a mean difference of 16 points on the Skindex-29 (SD\u00b122) with 80% power, based on a one-sided two-sample\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      test with \u03b1=0.05, accounting for 10% attrition. Secondary outcomes included validated subjective and objective measures. Intention-to-treat, per protocol, and regression analysis based on prior steroid exposure were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      From October 2015 to July 2018, 202 women were screened, 52 were randomized, and 51 completed a 6-month follow-up. No significant difference was found in baseline demographics, symptoms, and physician assessment scores. There was greater improvement in the Skindex-29 score in the laser arm at 6-months (10.9 point effect size, 95% CI 3.42\u201318.41;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.007). Overall, 89% (23\/27) of patients in the laser group rated symptoms as being \u201cbetter or much better\u201d compared with 62% (13\/24) of patients in the steroid group,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.07. More patients (81%, 21\/27) were \u201csatisfied or very satisfied\u201d with laser treatment compared with steroid treatment (41%, 9\/24);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.01. After stratification for previous steroid use, the significant change of Skindex-29 score was only seen in the previously exposed group. There was one adverse event in each group: minor burning and blistering at the laser site and reactivation of genital herpes 1 week after starting steroid.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>\n                      Fractionated CO\n                      <jats:sub>2<\/jats:sub>\n                      laser treatment showed significant improvement in subjective symptoms and objective measures compared with clobetasol propionate, without serious safety or adverse events at 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT02573883.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000004332","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T15:38:05Z","timestamp":1620574685000},"page":"968-978","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["Clobetasol Compared With Fractionated Carbon Dioxide Laser for Lichen Sclerosus"],"prefix":"10.1097","volume":"137","author":[{"given":"Linda S.","family":"Burkett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moiuri","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zeymo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Brunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl B.","family":"Iglesia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamadermatol.2015.0644","article-title":"Reduced risk of squamous cell carcinoma with adequate treatment of vulvar lichen sclerosus","volume":"151","author":"Cooper","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0046-8177(98)90198-8","article-title":"Vulvar lichen sclerosus and squamous cell carcinoma: a cohort, case control, and investigational study with historical perspective; implications for chronic inflammation and sclerosis in the development of neoplasia","volume":"29","author":"Carlson","year":"1998","journal-title":"Hum Pathol"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamadermatol.2015.0643","article-title":"Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women","volume":"151","author":"Lee","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archderm.140.6.709","article-title":"Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease","volume":"140","author":"Renaud-Vilmer","year":"2004","journal-title":"Arch Dermatol"},{"key":"R6-20250423","first-page":"37","article-title":"Clinical and histologic effects of topical treatments of vulval lichen sclerosus. A critical evaluation","volume":"38","author":"Bracco","year":"1993","journal-title":"J Reprod Med"},{"key":"R7-20250423","first-page":"790","article-title":"Lichen sclerosus. Therapy with clobetasol propionate","volume":"43","author":"Lorenz","year":"1998","journal-title":"J Reprod Med"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaad.2014.02.019","article-title":"A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus","volume":"71","author":"Funaro","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijgo.2006.09.018","article-title":"Topical testosterone versus clobetasol for vulvar lichen sclerosus","volume":"96","author":"Ayhan","year":"2007","journal-title":"Int J Gynaecol Obstet"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/archderm.140.6.702","article-title":"Does treatment of vulvar lichen sclerosus influence its prognosis?","volume":"140","author":"Cooper","year":"2004","journal-title":"Arch Dermatol"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10103-014-1677-2","article-title":"Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment","volume":"30","author":"Zerbinati","year":"2015","journal-title":"Lasers Med Sci"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/GME.0000000000000401","article-title":"Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study","volume":"22","author":"Salvatore","year":"2015","journal-title":"Menopause"},{"key":"R13-20250423","first-page":"1148","article-title":"Successful carbon dioxide laser therapy for refractory anogenital lichen sclerosus","volume":"30","author":"Peterson","year":"2004","journal-title":"Dermatol Surg"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2133.1997.tb14943.x","article-title":"Treatment of lichen sclerosus with carbon dioxide laser vaporization","volume":"136","author":"Kartamaa","year":"1997","journal-title":"Br J Dermatol"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/ajd.12305","article-title":"Fractional carbon dioxide laser in recalcitrant vulval lichen sclerosus","volume":"57","author":"Lee","year":"2016","journal-title":"Australas J Dermatol"},{"key":"R16-20250423","first-page":"469","article-title":"Laser therapy of vulvar lichen sclerosus et atrophicus","volume":"34","author":"Stuart","year":"1991","journal-title":"Can J Surg"},{"key":"R17-20250423","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/LGT.0000000000000512","article-title":"Fractionated CO2 laser as therapy in recalcitrant lichen sclerosus","volume":"24","author":"Balchander","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"R18-20250423","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jogc.2019.01.023","article-title":"Efficacy of non-ablative laser therapy for lichen sclerosus: a randomized controlled trial","volume":"41","author":"Bizjak Ogrinc","year":"2019","journal-title":"J Obstet Gynaecol Can"},{"key":"R19-20250423","doi-asserted-by":"crossref","DOI":"10.3843\/GLOWM.10023","article-title":"Lasers in gynecology","author":"DeLeon","year":"2008","journal-title":"Glob Libr Womens Med"},{"key":"R20-20250423","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","article-title":"Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases","volume":"133","author":"Chren","year":"1997","journal-title":"Arch Dermatol"},{"key":"R21-20250423","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/jid.2009.404","article-title":"Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors","volume":"130","author":"Prinsen","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R22-20250423","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/jid.2010.51","article-title":"Interpretation of quality-of-life scores","volume":"130","author":"Chren","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R23-20250423","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijsu.2011.09.004","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"9","author":"Schulz","year":"2011","journal-title":"Int J Surg"},{"key":"R24-20250423","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/13697137.2014.899347","article-title":"A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study","volume":"17","author":"Salvatore","year":"2014","journal-title":"Climacteric"},{"key":"R25-20250423","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/GME.0b013e318282600b","article-title":"The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women","volume":"20","author":"Erekson","year":"2013","journal-title":"Menopause"},{"issue":"Suppl","key":"R26-20250423","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/0378-5122(95)00956-6","article-title":"Urogenital ageing: an old problem newly recognized","volume":"22","author":"Bachmann","year":"1995","journal-title":"Maturitas"},{"key":"R27-20250423","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1097\/AOG.0000000000003616","article-title":"Elective female genital cosmetic surgery. ACOG Committee Opinion No. 795. American College of Obstetricians and Gynecologists","volume":"135","year":"2020","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:05:29Z","timestamp":1745420729000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004332"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004332","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"2020-11-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}